NCT02052141 - Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2014

Primary Completion Date

May 4, 2017

Study Completion Date

May 4, 2017

Conditions

Hereditary Angioedema (HAE)

Interventions

BIOLOGICAL

CINRYZE 500

500 Units of CINRYZE administered by IV injection

BIOLOGICAL

CINRYZE 1000

1000 Units of CINRYZE administered by IV injection

Trial Locations (8)

Klinikum der J.W. Goethe Universitat, Frankfurt

Tel Aviv Sourasky Medical Center, Tel Aviv

HZRM Hamophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf

Asthma and Allergy Associates, P.C, Colorado Springs

Nevada Access to Research and Education Society, Las Vegas

Oregon Allergy Associates, Eugene

Clinical County Hospital Mures, Târgu Mureş

Instituto Nacional de Pediatria, Mexico City